Change of Adviser

RNS Number : 8529C

Venn Life Sciences Holdings PLC

25 January 2018

 

25 January 2018

Venn Life Sciences Holdings plc

("Venn" or the "Company" or the "Group")

Appointment of Nominated Adviser and Broker

Venn Life Sciences Holdings plc, the AIM drug development services organisation, announces the appointment of Cenkos Securities plc as its Nominated Adviser and Broker with immediate effect.

Enquiries:

Venn Life Sciences Holdings plc	www.vennlifesciences.com
Allan Wood, Non-Executive Chairman	Tel: [phone]
Tony Richardson, Chief Executive Officer	Tel: [phone]
Cenkos (Nominated Adviser and Broker)	Tel: [phone]
Mark Connelly/Steve Cox (Corporate Finance)
Davy (ESM Adviser and Broker)	Tel: [phone]
Fergal Meegan / Matthew de Vere White (Corporate Finance)
Hybridan LLP ( Joint Broker)	Tel: [phone]
Claire Louise Noyce

About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences is available on their website - www.vennlifesciences.com

 

END

 

 

APPVZLFLVFFBBBE